AU2003223684A1 - Lxr modulators for the treatment of cardiovascular diseases - Google Patents

Lxr modulators for the treatment of cardiovascular diseases

Info

Publication number
AU2003223684A1
AU2003223684A1 AU2003223684A AU2003223684A AU2003223684A1 AU 2003223684 A1 AU2003223684 A1 AU 2003223684A1 AU 2003223684 A AU2003223684 A AU 2003223684A AU 2003223684 A AU2003223684 A AU 2003223684A AU 2003223684 A1 AU2003223684 A1 AU 2003223684A1
Authority
AU
Australia
Prior art keywords
treatment
cardiovascular diseases
lxr modulators
lxr
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003223684A
Inventor
Thomas Arrhenius
Jie-Fei Cheng
Alex M. Nadzan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AU2003223684A1 publication Critical patent/AU2003223684A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AU2003223684A 2002-04-23 2003-04-21 Lxr modulators for the treatment of cardiovascular diseases Abandoned AU2003223684A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37465002P 2002-04-23 2002-04-23
US60/374,650 2002-04-23
PCT/US2003/012391 WO2003090732A1 (en) 2002-04-23 2003-04-21 Lxr modulators for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
AU2003223684A1 true AU2003223684A1 (en) 2003-11-10

Family

ID=29270535

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003223684A Abandoned AU2003223684A1 (en) 2002-04-23 2003-04-21 Lxr modulators for the treatment of cardiovascular diseases

Country Status (2)

Country Link
AU (1) AU2003223684A1 (en)
WO (1) WO2003090732A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
WO2005092856A1 (en) * 2004-03-26 2005-10-06 F. Hoffmann-La Roche Ag Tetrahydrocarbazoles and derivatives
BRPI0512699A (en) 2004-06-28 2008-04-01 Hoffmann La Roche compounds, process for the manufacture of compounds, pharmaceutical compositions, method for therapeutic and / or prophylactic treatment of diseases that are modulated by lxr alpha and / or lxr beta agonists and use of such compounds
JP5575357B2 (en) * 2004-07-02 2014-08-20 第一三共株式会社 Tissue factor production inhibitor
BRPI0516842A (en) * 2004-10-01 2008-09-23 Hoffmann La Roche compounds, process for their manufacture, pharmaceutical compositions comprising them, method for the therapeutic and / or prophylactic treatment of diseases that are modulated by lxr alpha and / or lxr beta agonists and use of such compounds
BRPI0519620A2 (en) 2004-12-22 2009-02-25 F Hoffmamm La Roche Ag compounds, process for their manufacture, pharmaceutical compositions comprising them, method for the therapeutic and / or prophylactic treatment of diseases that are modulated by alpha-1xr and / or beta-1xr agonists and use of such compounds
US7998995B2 (en) * 2006-12-08 2011-08-16 Exelixis Patent Company Llc LXR and FXR modulators
FR2935380B1 (en) * 2008-08-29 2010-09-10 Galderma Res & Dev NOVEL HEXAFLUORO-2-BIPHENYL-ISOPROPANOL COMPOUNDS, MODULATORS OF LXRS-TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND THEIR APPLICATION AS MEDICAMENTS IN HUMAN OR VETERINARY MEDICINE AS WELL AS IN COSMETICS.
BR112013005425A2 (en) 2010-09-07 2018-05-02 Snu R&Db Foundation Three master teopin compounds and uses of these materials
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
CN109069461A (en) 2016-01-11 2018-12-21 洛克菲勒大学 The treatment method of illness relevant to marrow source property inhibition cell
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. Polymorphs and uses thereof
US11174220B2 (en) 2019-12-13 2021-11-16 Inspirna, Inc. Metal salts and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
EP1212065A4 (en) * 1999-07-08 2004-02-11 Tularik Inc Compositions and methods for raising hdl cholesterol levels
US7279477B2 (en) * 2001-01-26 2007-10-09 Chugai Seiyaku Kabushiki Kaisha Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
WO2002058690A2 (en) * 2001-01-26 2002-08-01 Chugai Seiyaku Kabushiki Kaisha Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors
US6924311B2 (en) * 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds

Also Published As

Publication number Publication date
WO2003090732A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
AU2003249244A1 (en) Methods for the treatment of neoplasms
AU2003238455A1 (en) Pyrrole compounds for the treatment of prostaglandin mediated diseases
AU2003286567A1 (en) Methods for the treatment of skin disorders
AU2003279338A1 (en) Phenethanolamine derivatives for the treatment of respiratory diseases
AU2003286728A1 (en) Compounds for the treatment of metabolic disorders
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
AU2003295890A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
AU2003220521A1 (en) Methods of treatment with lxr modulators
AU2003223684A1 (en) Lxr modulators for the treatment of cardiovascular diseases
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
AU2003251875A1 (en) Combination therapy for the treatment of neoplasms
AU2003903242A0 (en) Process for the treatment of wood
AU2003228614A1 (en) Lxr modulators
AU2003223538A1 (en) Methods for the treatment of cancer
AU2003215150A1 (en) Therapeutic compounds
AU2003260983A1 (en) Processes for the preparation of s-(-)-amlodipine
AU2003278559A1 (en) Herbal medicine containing cyclodextrins for the treatment of ear disorders
AU2003259833A1 (en) Methods of treating neurodegenerative diseases
AU2003222667A1 (en) 1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
AU2003220483A1 (en) Substituted pyrazolyl compounds for the treatment of inflammation
AU2002367890A1 (en) Process for the preparation of 4-methyl-thiazole-5-carbaldehyde intermediate
AU2002258798A1 (en) Methods for the treatment of hepatic disorders
GB0201025D0 (en) The treatment of degenerative diseases
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer
AU2003240174A1 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase